Status:
COMPLETED
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Lead Sponsor:
AbbVie
Conditions:
Rheumatoid Arthritis (RA)
Eligibility:
All Genders
18+ years
Brief Summary
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA).
- Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
- Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies.
- French Participants Only: Taking oral glucocorticoids ≥5 mg/day of prednisone or equivalent for at least 3 months prior to study start.
Exclusion
- \- Prior treatment with Upadacitinib.
Key Trial Info
Start Date :
October 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
1532 Patients enrolled
Trial Details
Trial ID
NCT04497597
Start Date
October 16 2020
End Date
May 15 2024
Last Update
April 13 2025
Active Locations (263)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Italiano La Plata /ID# 222190
La Plata, Buenos Aires, Argentina, 1902
2
CER Instituto Medico /ID# 222193
Quilmes, Buenos Aires, Argentina, 1878
3
Organizacion Medica de Investigacion (OMI) /ID# 222187
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1015
4
CIER Centro de Investigaciones en Enfermedades Reumaticas /ID# 231769
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1055